Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Axitinib induces senescence-associated cell death and necrosis in glioma cell lines: The proteasome inhibitor, bortezomib, potentiates axitinib-induced cytotoxicity in a p21(Waf/Cip1) dependent manner.

Morelli MB, Amantini C, Nabissi M, Cardinali C, Santoni M, Bernardini G, Santoni A, Santoni G.

Oncotarget. 2017 Jan 10;8(2):3380-3395. doi: 10.18632/oncotarget.13769.

2.

Nuclear factor-κB in glioblastoma: insights into regulators and targeted therapy.

Cahill KE, Morshed RA, Yamini B.

Neuro Oncol. 2016 Mar;18(3):329-39. doi: 10.1093/neuonc/nov265. Epub 2015 Nov 2. Review.

3.

Efficacy of low dose temozolomide in combination with bortezomib in U87 glioma cells: a flow cytometric analysis.

Vlachostergios PJ, Papandreou CN.

Arch Med Sci. 2015 Apr 25;11(2):307-10. doi: 10.5114/aoms.2013.36919. Epub 2013 Aug 12.

4.

The challenges and the promise of molecular targeted therapy in malignant gliomas.

Wang H, Xu T, Jiang Y, Xu H, Yan Y, Fu D, Chen J.

Neoplasia. 2015 Mar;17(3):239-55. doi: 10.1016/j.neo.2015.02.002. Review.

5.

Medical therapy of gliomas.

Ahluwalia MS, Chang SM.

J Neurooncol. 2014 Sep;119(3):503-12. doi: 10.1007/s11060-014-1495-1. Epub 2014 Jul 2. Review.

6.

PSMD9 expression predicts radiotherapy response in breast cancer.

Langlands FE, Dodwell D, Hanby AM, Horgan K, Millican-Slater RA, Speirs V, Verghese ET, Smith L, Hughes TA.

Mol Cancer. 2014 Mar 28;13:73. doi: 10.1186/1476-4598-13-73.

7.

Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors.

Dunbar EM, Coats BS, Shroads AL, Langaee T, Lew A, Forder JR, Shuster JJ, Wagner DA, Stacpoole PW.

Invest New Drugs. 2014 Jun;32(3):452-64. doi: 10.1007/s10637-013-0047-4. Epub 2013 Dec 3.

8.

Concurrent whole brain radiotherapy and bortezomib for brain metastasis.

Lao CD, Friedman J, Tsien CI, Normolle DP, Chapman C, Cao Y, Lee O, Schipper M, Van Poznak C, Hamstra D, Lawrence T, Hayman J, Redman BG.

Radiat Oncol. 2013 Aug 21;8:204. doi: 10.1186/1748-717X-8-204.

9.

Inhibition of prolyl 4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide resistance in malignant glioma via the endoplasmic reticulum stress response (ERSR) pathways.

Sun S, Lee D, Ho AS, Pu JK, Zhang XQ, Lee NP, Day PJ, Lui WM, Fung CF, Leung GK.

Neuro Oncol. 2013 May;15(5):562-77. doi: 10.1093/neuonc/not005. Epub 2013 Feb 26.

10.

HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivo.

Huang H, Liu N, Yang C, Liao S, Guo H, Zhao K, Li X, Liu S, Guan L, Liu C, Xu L, Zhang C, Song W, Li B, Tang P, Dou QP, Liu J.

PLoS One. 2012;7(12):e52576. doi: 10.1371/journal.pone.0052576. Epub 2012 Dec 20.

11.

Proteasome inhibitor MG132 induces NAG-1/GDF15 expression through the p38 MAPK pathway in glioblastoma cells.

Shimizu S, Kadowaki M, Yoshioka H, Kambe A, Watanabe T, Kinyamu HK, Eling TE.

Biochem Biophys Res Commun. 2013 Jan 25;430(4):1277-82. doi: 10.1016/j.bbrc.2012.11.137. Epub 2012 Dec 19.

12.

Radiosensitization of Cancer Cells by Inactivation of Cullin-RING E3 Ubiquitin Ligases.

Wei D, Morgan MA, Sun Y.

Transl Oncol. 2012 Oct;5(5):305-12. Epub 2012 Oct 1.

13.

Towards personalized therapy for patients with glioblastoma.

Shirai K, Chakravarti A.

Expert Rev Anticancer Ther. 2011 Dec;11(12):1935-44. doi: 10.1586/era.11.103. Review.

14.

DNA damage response and repair: insights into strategies for radiation sensitization of gliomas.

Kesari S, Advani SJ, Lawson JD, Kahle KT, Ng K, Carter B, Chen CC.

Future Oncol. 2011 Nov;7(11):1335-46. doi: 10.2217/fon.11.111. Review.

15.

Recent advancements in multimodality treatment of gliomas.

Hadziahmetovic M, Shirai K, Chakravarti A.

Future Oncol. 2011 Oct;7(10):1169-83. doi: 10.2217/fon.11.102. Review.

16.

A phase I study of bortezomib and temozolomide in patients with advanced solid tumors.

Portnow J, Frankel P, Koehler S, Twardowski P, Shibata S, Martel C, Morgan R, Cristea M, Chow W, Lim D, Chung V, Reckamp K, Leong L, Synold TW.

Cancer Chemother Pharmacol. 2012 Feb;69(2):505-14. doi: 10.1007/s00280-011-1721-x. Epub 2011 Aug 18.

17.

Therapeutic effect of neural stem cells expressing TRAIL and bortezomib in mice with glioma xenografts.

Balyasnikova IV, Ferguson SD, Han Y, Liu F, Lesniak MS.

Cancer Lett. 2011 Nov 28;310(2):148-59. doi: 10.1016/j.canlet.2011.06.029. Epub 2011 Jul 1.

18.

Molecular targeting of glioblastoma: Drug discovery and therapies.

Bai RY, Staedtke V, Riggins GJ.

Trends Mol Med. 2011 Jun;17(6):301-312. doi: 10.1016/j.molmed.2011.01.011. Epub 2011 Mar 14. Review.

19.

Stressed to death: targeting endoplasmic reticulum stress response induced apoptosis in gliomas.

Johnson GG, White MC, Grimaldi M.

Curr Pharm Des. 2011;17(3):284-92. Review.

20.

Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy.

Gong X, Schwartz PH, Linskey ME, Bota DA.

Neurology. 2011 Mar 29;76(13):1126-34. doi: 10.1212/WNL.0b013e318212a89f. Epub 2011 Feb 23.

Supplemental Content

Support Center